金山科研平台，产品价格货期咨询微信：jinshanbio Source:Mouse myeloma cell line, NS0-derived Accession #:O09030 N-terminal Sequence Analysis:Ala25 Structure:Disulfide-linked homodimer Purity:>97%, by SDS-PAGE under reducing conditions and visualized by silver stain. Predicted Molecular Mass:63 kDa (monomer) SDS-PAGE:100-120 kDa, reducing conditions Activity:Measured by its ability to inhibit IL-13-dependent proliferation of TF‑1 human erythroleukemic cells. Kitamura, T. et al. (1989) J. Cell Physiol. 140:323.The ED₅₀ for this effect is typically 0.2 - 0.8 µg/mL in the presence of 4 ng/mL rmIL-13. Molecule Information: IL-13 R alpha 1 Long Name: Interleukin 13 Receptor alpha 1 Aliases: CD213a1; IL13RA1 Entrez Gene IDs: 3597 (Human); 16164 (Mouse) Background: IL-13 Receptors Two members of the type 5 subfamily of type I cytokine receptors can serve as receptors for IL-13. IL-13 can bind to IL-13 R alpha 1 (CD213a1; previously designated IL-13 R alpha or NR4) with low affinity, then recruits the IL-4 R alpha chain to form a high affinity receptor, causing downstream STAT6 activation. Alternately, IL-13 can bind IL-13 R alpha 2 (CD213a2) with high affinity; this interaction does not cause activation of STAT6, but does induce TGF-beta production. IL-13 R alpha 1 and IL-13 R alpha 2 each have three extracellular fibronectin type III domains, two cytokine receptor homology modules and a WSXWS motif typical of the class I cytokine receptor family, but IL-13 R alpha 2 has a much shorter cytoplasmic tail. IL-13 R subunits can be expressed on monocytes, macrophages, fibroblasts, human B cells, basophils, eosinophils, endothelial cells, and smooth muscle cells.